Rotigotin bei speziellen Fragestellungen

As a non-ergolinic dopamine agonist for transdermal administration, rotigotin is now available as an initial therapy or as combination therapy with L-dopa for the late stages of the disease. This form of administration makes its use independent of gastroparesis or dysphagia and thus opens a new option for perioperative situations. Furthermore, recent study results reveal a positive effect on early morning akinesia, dyskinesias/fluctuations and sleep disturbances associated with Parkinson's disease . Areas of application to be examined in the future are its influence on depressive disorders and its use in poorly compliant patients with Parkinson's disease, cognitive deficits or in cases of hallucinations and psychoses.